Brought to you by 
Lundbeck, Teva to develop and market oral drug for MS
14 Mar 2001
Executive Summary
H. Lundbeck (drugs to treat psychiatric and neurological diseases) and Teva Pharmaceuticals (generic drugs) will co-develop and co-market in Europe and several overseas markets, an oral formulation of Teva's Copaxone (glatiramer acetate).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lundbeck, Teva to develop and market oral drug for MS
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice